A Phase 1b, Randomized, Double-blind (Sponsor Open), Placebo Controlled Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf 04447943, Co-administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease
Phase of Trial: Phase I
Latest Information Update: 08 Nov 2016
At a glance
- Drugs PF 4447943 (Primary)
- Indications Sickle cell anaemia
- Focus Adverse reactions
- Sponsors Pfizer
- 31 Oct 2016 Status changed from recruiting to completed.
- 14 Sep 2016 Planned End Date changed from 1 Aug 2016 to 1 Sep 2016.
- 11 Jul 2016 Planned End Date changed from 1 Jul 2016 to 1 Aug 2016.